Trials in San Diego, California
Here are the top 10 medical studies for lung cancer in San Diego, California
Popular Filters
Phase 3 Trials
Checkpoint Inhibitor
Pembrolizumab + Chemoradiation +/- Olaparib for Stage III Lung Cancer
Recruiting1 awardPhase 3
Fullerton, California
This trial will compare the efficacy of three different treatments for unresectable, locally advanced NSCLC. Arm 1 will receive pembrolizumab concurrently with chemoradiation, followed by pembrolizumab with olaparib placebo. Arm 2 will receive the same treatment as Arm 1, but will take olaparib instead of the placebo. Arm 3 will receive concurrent chemoradiation therapy followed by durvalumab. The primary hypothesis is that pembrolizumab with concurrent chemoradiation and olaparib is superior to durvalumab with respect to PFS and OS.
Tyrosine Kinase Inhibitor
Osimertinib + Chemotherapy for Lung Cancer
Recruiting1 awardPhase 3
Irvine, California
This trial is testing osimertinib, a drug that targets cancer cells, either by itself or with chemotherapy. It focuses on patients with a specific type of lung cancer that has a mutation in the EGFR gene. The drug works by stopping the growth of cancer cells.
Small Molecule Drug
Adagrasib + Pembrolizumab for Lung Cancer
Recruiting1 awardPhase 2 & 3
Rancho Mirage, California
This trial tests two drugs, MRTX849 and pembrolizumab, in patients with advanced lung cancer who have a specific genetic mutation. MRTX849 targets the mutation to stop cancer growth, while pembrolizumab boosts the immune system to fight the cancer. The study aims to see how well these treatments work alone and together.
Radiation Therapy
Whole Brain Radiotherapy + Stereotactic Radiosurgery for Brain Metastasis
Recruiting2 awardsPhase 3
Irvine, California
This trial is testing whether adding whole brain radiation therapy with hippocampal avoidance (to protect memory) and memantine (to protect thinking) to standard stereotactic radiosurgery (a high dose of radiation only to the small areas of cancer in the brain) is more effective than stereotactic radiosurgery alone in treating patients with cancer that has spread to the brain and come back in other areas of the brain after earlier stereotactic radiosurgery.
Checkpoint Inhibitor
Ociperlimab + Tislelizumab vs Pembrolizumab for Lung Cancer
Recruiting1 awardPhase 3
Fullerton, California
This trial is testing a combination of two drugs, ociperlimab and tislelizumab, to see how well they work together. Tislelizumab is an anti-PD-1 antibody developed by BeiGene, showing promise in various cancers and approved in China for several uses. It targets adults with a specific type of advanced lung cancer that has high levels of a protein called PD-L1. The drugs aim to boost the body's immune system to better recognize and attack cancer cells.
Small Molecule Drug
Adagrasib vs Docetaxel for Non-Small Cell Lung Cancer
Recruiting2 awardsPhase 3
Cerritos, California
This trial is testing a new drug called adagrasib against an existing chemotherapy drug, docetaxel. It focuses on patients with advanced lung cancer who have a specific genetic mutation (KRAS G12C) and have already had treatment. The new drug aims to block this mutation in cancer cells to stop their growth.
Trials With No Placebo
Topoisomerase I inhibitor
BAY 1895344 + Chemotherapy for Lung Cancer
Recruiting1 awardPhase 1
Orange, California
This trial tests the safety and best dose of a new drug combined with chemotherapy in patients with advanced solid tumors. The goal is to see if this combination can slow tumor growth more effectively than chemotherapy alone. The new drug blocks enzymes needed for tumor growth, while the chemotherapy drugs kill or stop the tumor cells from dividing. The chemotherapy drugs used in this trial are known to be effective in treating various cancers.
Monoclonal Antibodies
AZD8701 + Durvalumab for Solid Cancers
Recruiting1 awardPhase 1
La Jolla, California
This trial is testing a new drug, AZD8701, alone and with an existing drug, Durvalumab, in adults with advanced cancers. The goal is to see if these treatments can stop cancer growth or help the immune system fight the cancer. The study focuses on patients whose cancers are hard to treat or have responded to similar treatments before. Durvalumab is a drug that helps the immune system fight cancer and has been used with other treatments to help patients live longer.
Monoclonal Antibodies
BCA101 + Pembrolizumab for Cancer
Recruiting1 awardPhase 1
La Jolla, California
This trial is testing BCA101, a new drug that targets specific cancer growth proteins, in patients with advanced cancers that haven't responded to other treatments. The drug works by blocking proteins that help the cancer grow and spread.
Monoclonal Antibodies
SAR408701 + Ramucirumab/Pembrolizumab for Lung Cancer
Recruiting1 awardPhase 2
Whittier, California
This trial is testing a new combination drug therapy for people with non-small cell lung cancer that has progressed despite other treatments. The goal is to see if the new therapy is safe and effective.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.